TABLE 1

Novel diabetes drugs: Findings of cardiovascular outcome studies

DrugFindings
Dipeptidyl peptidase-4 inhibitors
AlogliptinCardiovascular safety
Heart failure caution
LinagliptinaResults not available
SaxagliptinCardiovascular safety
Heart failure caution
SitagliptinCardiovascular safety
Glucagon-like peptide-1 receptor agonists
AlbiglutideaResults not available
DulaglutideaResults not available
ExenatideaResults not available
LiraglutidebCardiovascular benefit
LixisenatideCardiovascular safety
Semaglutideb,cCardiovascular benefit
Sodium-glucose cotransporter-2 inhibitors
CanagliflozinaCardiovascular benefit Amputation caution
DapagliflozinaResults not available
EmpagliflozinCardiovascular benefit
Cardiovascular death benefit
ErtugliflozinaResults not available

  • ↵a Cardiovascular outcomes trials ongoing.

  • ↵b Cardiovascular effects currently under review by the US Food and Drug Administration.

  • ↵c Not available in United States.